Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ArcticZymes Technologies ASA (AZT.OL)
Tromsø, NO
ArcticZymes Technologies ASA is a leading life sciences firm dedicated to the development, production, and global sale of recombinant enzymes. These specialized enzymes are essential for a variety of applications, including molecular research, in vitro diagnostic testing, and processes within biomanufacturing. The company's diverse product lineup includes several key enzymatic solutions. For example, its salt active nuclease is instrumental in eliminating nucleic acids during the manufacturing of viral vectors, recombinant proteins, and other critical reagents. ArcticZymes also supplies shrimp alkaline phosphatase and accompanying kits, which are vital for purifying samples before both Sanger and next-generation sequencing. Another significant product is cod UNG, frequently utilized in viral and other molecular diagnostic assays, alongside double-strand specific DNases and their related kits, engineered for the efficient removal of double-stranded DNA. The firm's polymerases are designed to drive technological progress in life science, molecular diagnostics, NGS, and synthetic biology. Furthermore, it offers proteinase for applications in microbiological diagnostics and liquid biopsies, and ligases, which are crucial for connecting DNA and RNA fragments. ArcticZymes Technologies boasts a broad international presence, serving markets in Norway, Germany, Lithuania, Italy, various other European nations, the United States, and additional global territories. Founded in 1990, the enterprise was initially known as Biotec Pharmacon ASA until June 2020, when it officially rebranded to its current name. Its corporate headquarters are located in Tromsø, Norway.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.28% | +0.00% | +5.08% | -7.17% | -10.00% | -2.36% | +22.85% | -44.20% | -76.48% | +77.68% | -15.30% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+7.9% ★ Q1'26: +36.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+11.8% Q1'26: +119.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+8.4% Q1'26: -0.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+2.5% ★ Q1'26: -2.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+1.4% ★ Q1'26: -3.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-2.6% ★ Q1'26: -1.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.79× ★ Q1'26: 3.07× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
24.08M
est: 47.62M (-49.4%)
|
25.91M
est: 28.13M (-7.9%)
|
23.03M
est: 31.65M (-27.2%)
|
21.48M
est: 55.82M (-61.5%)
|
53.28M
est: 56.00M (-4.9%)
|
71.90M
est: 70.15M (+2.5%)
|
66.69M
est: 67.00M (-0.5%)
|
66.77M
est: 66.00M (+1.2%)
|
77.25M
est: 79.81M (-3.2%)
|
93.45M
est: 100.69M (-7.2%)
|
127.97M
est: 120.51M (+6.2%)
|
136.97M
est: 137.12M (-0.1%)
|
118.94M
est: 117.80M (+1.0%)
|
104.35M
est: 106.53M (-2.0%)
|
112.62M
est: 111.10M (+1.4%)
|
136.95M
133.90M – 140.00M
+23.3% YoY
|
162.15M
161.00M – 163.30M
+18.4% YoY
|
189.30M
186.64M – 191.96M
+16.7% YoY
|
| EBITDA |
-82.14M
est: 16.75M (-590.4%)
|
-25.49M
est: -8.50M (-199.8%)
|
-18.02M
est: -9.62M (-87.4%)
|
-22.33M
est: -16.97M (-31.6%)
|
-15.56M
est: 19.70M (-179.0%)
|
-18.48M
est: 24.67M (-174.9%)
|
-22.94M
est: 23.56M (-197.3%)
|
-10.33M
est: -22.51M (+54.1%)
|
3.07M
est: -9.72M (+131.5%)
|
45.18M
est: 35.41M (+27.6%)
|
62.95M
est: 42.38M (+48.5%)
|
47.85M
est: 48.22M (-0.8%)
|
31.64M
est: 32.54M (-2.8%)
|
17.51M
est: 29.43M (-40.5%)
|
11.96M
est: 30.69M (-61.0%)
|
37.83M
36.99M – 38.68M
+23.3% YoY
|
44.79M
44.48M – 45.11M
+18.4% YoY
|
52.29M
51.56M – 53.03M
+16.7% YoY
|
| EBIT |
-85.12M
est: 14.82M (-674.3%)
|
-28.43M
est: -10.22M (-178.1%)
|
-19.85M
est: -11.57M (-71.6%)
|
-24.50M
est: -20.40M (-20.1%)
|
-18.49M
est: 17.43M (-206.1%)
|
-20.36M
est: 21.83M (-193.2%)
|
-24.92M
est: 20.85M (-219.5%)
|
-13.17M
est: -24.54M (+46.4%)
|
127.0K
est: -13.12M (+101.0%)
|
42.79M
est: 31.34M (+36.6%)
|
59.95M
est: 37.51M (+59.8%)
|
42.83M
est: 42.68M (+0.4%)
|
25.26M
est: 26.46M (-4.5%)
|
10.93M
est: 23.93M (-54.3%)
|
2.81M
est: 24.96M (-88.7%)
|
30.76M
30.08M – 31.45M
+23.3% YoY
|
36.43M
36.17M – 36.68M
+18.4% YoY
|
42.52M
41.93M – 43.12M
+16.7% YoY
|
| Net Income |
-99.37M
est: -229.87M (+56.8%)
|
-28.54M
est: -10.24M (-178.6%)
|
-20.10M
est: -11.59M (-73.5%)
|
-24.32M
est: -20.44M (-19.0%)
|
-17.34M
est: -21.02M (+17.5%)
|
-20.48M
est: -23.49M (+12.8%)
|
-24.94M
est: -32.03M (+22.1%)
|
-13.99M
est: -24.57M (+43.1%)
|
-7.18M
est: -13.78M (+47.9%)
|
83.12M
est: 7.47M (+1,012.2%)
|
46.38M
est: 46.62M (-0.5%)
|
32.86M
est: 36.11M (-9.0%)
|
19.43M
est: 14.62M (+32.8%)
|
8.47M
est: 4.10M (+106.8%)
|
9.88M
est: 5.98M (+65.2%)
|
18.20M
17.53M – 18.87M
+204.3% YoY
|
32.76M
31.36M – 34.17M
+80.0% YoY
|
48.10M
46.23M – 49.98M
+46.8% YoY
|
| SGA |
56.84M
est: 4.82M (+1,079.7%)
|
13.58M
est: 25.04M (-45.8%)
|
5.53M
est: 28.33M (-80.5%)
|
6.93M
est: 49.97M (-86.1%)
|
7.73M
est: 5.67M (+36.4%)
|
9.74M
est: 7.10M (+37.2%)
|
10.40M
est: 6.78M (+53.3%)
|
8.46M
est: 45.34M (-81.3%)
|
1.27M
est: 43.54M (-97.1%)
|
35.15M
est: 47.10M (-25.4%)
|
6.61M
est: 12.19M (-45.8%)
|
1.15M
est: 13.87M (-91.7%)
|
1.37M
est: 10.09M (-86.4%)
|
6.08M
est: 9.13M (-33.4%)
|
33.62M
est: 9.52M (+253.3%)
|
11.73M
11.47M – 11.99M
+23.3% YoY
|
13.89M
13.79M – 13.99M
+18.4% YoY
|
16.22M
15.99M – 16.44M
+16.7% YoY
|
| EPS |
-4.11
est: -4.31 (+4.6%)
|
-1.18
est: -0.81 (-46.6%)
|
-0.70
est: -0.83 (+15.6%)
|
-0.85
est: -0.36 (-137.7%)
|
-0.40
est: -0.31 (-29.0%)
|
-0.47
est: -0.44 (-6.8%)
|
-0.57
est: -0.60 (+5.0%)
|
-0.30
est: -0.30 (+0.0%)
|
-0.15
est: -0.11 (-36.4%)
|
1.67
est: 0.14 (+1,092.9%)
|
0.94
est: 0.87 (+7.6%)
|
0.65
est: 0.68 (-3.9%)
|
0.38
est: 0.28 (+34.9%)
|
0.17
est: 0.08 (+115.9%)
|
0.19
est: 0.12 (+65.2%)
|
0.35
0.34 – 0.36
+204.3% YoY
|
0.63
0.60 – 0.66
+80.0% YoY
|
0.93
0.89 – 0.96
+46.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | B | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | B | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap ETF DFIS | 0.00% | 59.2K | 0.39% |
| 2 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 25.4K | 0.22% |
| 3 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 10.0K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael Benjamin Akoh | Chief Executive Officer | 2M | male |
| Borge Sorvoll | Chief Financial Officer | 2M | male |
| Paul Blackburn | C.C.O | 2M | male |
| Marit Sjo Lorentzen | Vice President of Operations | 1M | — |
| Steve Dey | Global Director of Product Management & Marketing | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AZT.OL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
